Accurate detection of incident hepatitis C virus (HCV) infection is required to target and evaluate public health interventions, but acute infection is largely asymptomatic and difficult to detect using traditional methods. Our aim was to evaluate a previously developed HCV avidity assay to distinguish acute from chronic HCV infection. Plasma samples collected from recent seroconversion subjects in two large Australian cohorts were tested using the avidity assay, and the avidity index (AI) was calculated. Defining recent infection as <26 weeks, sensitivity (at AI cut-off of 20%) was estimated at 48% (95% CI:39-56%), 36% (95% CI:20-52%), and 65% (95% CI:54-75%) and MDRI was 116, 83, and 152 days for all genotypes, G1, and G3, respectively. Specificity (≥52 weeks infection duration, all genotypes) was 96% (95% CI:90-98%). HCV avidity testing has utility for detecting recent HCV infection in patients, and for assessing progress in reaching incidence targets for eliminating transmission, but variation in assay performance across genotype should be recognized. 
populations most at risk of infection, public health interventions can be implemented, and their effectiveness evaluated. However, HCV incidence can be difficult (and expensive) to measure using traditional epidemiological methods, which typically rely on following subjects over time to observe seroconversion. A reliable laboratory test for recent HCV infection would, therefore, be of considerable public health value.
Several HCV assays to measure acute/recent infection have been described [2] [3] [4] [5] [6] [7] [8] ; the majority of these are modified commercial assays measuring antibody avidity. Antibody avidity is the binding capacity of maturing antibody to antigen, which increases over time in primary infection. While HCV avidity assays have been shown to distinguish between acute and chronic infection, they may not differentiate between acute and resolved infection. 5, 6 Therefore, these assays cannot be used as a stand-alone test and require additional HCV markers, such as PCR or an IgM dilution series. 8, 9 We have previously described an HCV avidity assay, 8 which is a modified version of the Ortho HCV 3.0 ELISA Test System with Enhanced SAVekit (Ortho Clinical Diagnostics) using the antibodyantigen chaotropic agent, urea. The limitation recognized in this previous study was the small number of recently infected patients (N = 19) used to define the assay, as has been the case with many published avidity assay methods (Ns ≤ 50). [2] [3] [4] [5] [6] [7] Recently, Patel et al measured avidity in 568 PWIDs, of whom only 56 were seroconverters. 10 These authors' assay was also based on the Ortho ELISA using the chaotropic agent, diethylamine (DAE). In the current paper, we apply our urea-based avidity assay to two large well-described cohorts involving over 200 recently infected individuals. To our knowledge, this is the first study to examine HCV avidity according to genotype. 14 Plasma samples from participants fitting these criteria were identified and HCV avidity was measured (as described below 
| Laboratory testing
Antibody avidity was assessed using a modified version of the Ortho HCV 3.0 ELISA Test System with Enhanced SAVekit (Ortho Clinical Diagnostics). The chaotropic agent used in this study was 7M urea.
Two aliquots of each sample were tested simultaneously, one aliquot was treated with 7M urea and the other aliquot was treated with ORTHO kit wash buffer. The AI was calculated by taking the OD of the urea treated sample divided by the OD of the kit wash buffer treated sample and expressed as a percentage. The full method for this assay has previously been described. 8 The following modifications were in place for this study: (i) samples were initially diluted 1/500 with kit diluent; (ii) samples with an optical density (OD) <1.0 were re-tested at a 1/100 dilution; and (iii) samples with an OD ≥4.0 (saturation point on the plate reader) were re-tested at a dilution of 1/1500. AI was calculated and expressed as a percentage. Samples treated with buffer that had an OD < 1.0 were excluded from the study due to low antibody levels that could lead to inaccurate AI. All avidity testing was performed at the West of Scotland Specialist Virology Laboratory, and was conducted blinded to any of the epidemiological and HCV information (eg, duration of infection, HCV RNA level, and genotype).
Detection of quantification of HCV RNA for ATAHC samples was performed using the Versant TMA assay (detection <10 IU/mL); HITSp samples were tested on the COBAS AmpliPrep/COBAS TaqMan HCV assay (detection <15 IU/mL).
For avidity analysis, HCV RNA-positivity is required; therefore, samples were categorized as non-viraemic and viraemic using HCV RNA definitions of <250 and ≥250 IU/mL, respectively. The former The sensitivity and specificity of AI (according to specific AI thresholds) as a test for recent HCV infection were estimated via logistic regression models [16] [17] [18] fitted to the longitudinal dataset.
Although these measures will depend on properties of the population being tested, such as characteristics of the distribution of time since infection, sensitivity and specificity are appropriate metrics for individual patient-level detection of recent infection, and thus have clinical application. 19 Regression models were specified using generalized estimating equations (GEE), which is an appropriate method for handling non-independent (clustered) data. 95% confidence intervals (CIs) for the two indicators were derived using robust standard errors.
Sensitivity (for infections with an estimated time since infection of <8
weeks and of <26 weeks) and specificity (for infections with an estimated time since infection ≥52 weeks) were estimated for AI cutoff values ranging from 10% through 40%, in steps of 10%. Estimation of these parameters was carried out for all genotypes, and for G1 and G3 separately.
Finally, to enable the data to be applicable for incidence monitoring at the population-level, 17 further measures of assay performance was computed: mean duration of recent infection (MDRI) and false recency rate (MDRI). The former measure was calculated using the binomial regression method, 20 using a maximum duration of infection value T of 365 days (where T is the defined threshold of duration of infection beyond which AI values below the cut-off are classified as "false recent"), for all genotypes and separately for genotype 1 and 3, for AI cut-off values from 10% to 40%.
Bootstrapping was used to determine 95% confidence intervals. FRR was computed with respect to the same value of T, and is identical to 100 minus specificity (see above for computation method).
| RESULTS
The initial dataset consisted of a total of 635 samples, representing a total of 269 subjects ( Figure 1 ). To improve the accuracy of the estimation of the date of infection, participants who were recent asymptomatic seroconverters but whose duration of infection was uncertain (≥1 year between last negative and first positive test date; n = 68) were excluded. Thus, 567 samples (from 215 participants) were included in the avidity analysis ( Figure 1 ), of which 304 samples had HCV RNA ≥250 IU/mL and 263 samples had HCV RNA <250 IU/mL; the vast majority (97%) of the latter samples were RNA negative.
| Characteristics of the study cohort by viraemic category
Demographic and clinical characteristics of the cohort, according to RNA category at baseline are shown in Table 1 . The majority of subjects (n = 215) were male (73%), acquired their HCV infection through injecting drug use (85%), were infected with HCV genotype 1 or 3 (47% and 37% among the viraemic group, respectively), were estimated to have acquired infection ≤26 weeks before the date of baseline sample (68%), and were asymptomatic (60%). The average age at baseline was 31 years. Eighteen percent of the study cohort was coinfected with HIV.
| Avidity index (AI) by viraemic category
An AI value could be determined for 446 samples (from 180 subjects), including 226 samples (from 127 subjects) with HCV RNA ≥250 IU/mL. For the samples with HCV RNA < 250 IU/mL, there was no clear relationship between median AI and increasing duration of infection, whereas for viraemic (HCV RNA ≥250 IU/mL) samples, median AI increased monotonically with duration of infection category; subsequent analysis was therefore confined to viraemic samples.
| Factors associated with AI among viraemic cases
At baseline, several characteristics differed between high AI (≥30) and low AI (<30) categories (Table 2) 
| Sensitivity and specificity by genotype among viraemic samples
For individual-level detection of recent infection, the diagnostic test metrics sensitivity and specificity were computed via logistic regression. Based on the longitudinal dataset (containing both baseline and follow-up samples: n = 226), sensitivity (derived from samples with estimated duration of infection <26 weeks) ranged from 34% (95% CI:
26-42%) with an AI cut-off of 10%, to 61% (95% CI: 53-68%) with an AI cut-off of 40% (Table 3) . For the early stage of recent infection (defined as an estimated duration of infection <8 weeks), the overall sensitivity at an AI cut-off value of 20% increased to 91% (95% CI: 75-97%). An AI cut-off value of 20% attained optimal specificity of 96% (95% CI: 90-98%) and sensitivity of 48% (95% CI 39-56%).
Sensitivity also differed across genotype category. At an AI cutoff of 20%, the sensitivity (based on estimated duration of infection <26 weeks) for G1 samples (n = 86) was lower than for G3 samples HIV infection, n (%) 39 (18) 1 (2) 38 (24) IQR, interquartile range. 
| Interpretation of our findings in relation to previous studies
Our study population, of whom the majority (85%) acquired HCV through injecting drug use, is representative of patients with newly acquired HCV in developed countries. Genotypes 1 and 3 were the most commonly occurring HCV genotypes, reflecting the global HCVinfected population as a whole.
21,22
The finding of a decreased likelihood of low AI with increasing duration of infection is consistent with previous studies. 2, 3, 6 The overall sensitivity and specificity of the assay determined here was low compared to what has been previously published by us (100% and 99%, respectively 8 ) and by others (98% and 100%, respectively 6 ).
However, both our previous study and that of -is 4 to 6 months. 6, 8 Two definitions of time since infection were compared (<26 weeks and <8 weeks, where the latter is more likely to be true recent infection), and we found that the overall sensitivity of the assay was notably higher for the shorter time since infection, as has been highlighted previously. 9 The improvement in sensitivity with a duration of infection of <8 weeks was greater for genotype 1, indicating that the mean duration of infection for the assay is shortened for this genotype. Genotype differences have been found when viral load was compared suggesting adaptive immune responses may vary across genotype. 23 Similar variation in the duration of recent infection has been reported among different HIV subtypes.
24,25
The present analysis did not identify co-infection with HIV as a unique predictor of low AI value; this was possibly due to a lack of power. It has been demonstrated that HIV infection can cause a delay in anti-HCV production, with some HIV-positive individuals having no detectable anti-HCV up to 1 year post-HCV infection. 26 The prevalence of HIV among PWID varies by setting, 27, 28 and given that there was a substantial prevalence of HIV co-infection among our study Subjects with an ALT > 400 IU/mL had a twofold higher likelihood of a low AI, compared with asymptomatic patients, although this was not statistically significant. The ALT level in chronically infected patients is generally lower than in symptomatic, acutely infected HCV patients. 30 Therefore, elevated ALT and low avidity can indicate recent infection. However, in patients with an acute exacerbation of chronic HCV, ALT levels can be >400 IU/mL.
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TABLE 2 Factors associated with low avidity index among people with recent HCV infection and HCV RNA ≥250 in the baseline dataset (n = 121; reduction from n = 157 as reported in Table 1 was due to exclusion of samples with very low or high antibody levels) 
| Possible clinical and epidemiological applications of the assay
Previously, the major clinical utility in distinguishing recent from chronic HCV infection was to identify patients for early treatment with interferon-based antiviral therapy, which is associated with improved outcomes. [32] [33] [34] [35] With the success of direct-acting antivirals (DAAs) in treating chronic infection, the need to identify acute infections for early treatment may no longer be as important. 36, 37 Nevertheless, using the effective new therapies for the treatment of patients with recent infection may have value in preventing the onward transmission of infection. 38 The estimates of the traditional diagnostic test metrics presented here, sensitivity and specificity, are useful for these applications.
Although the sensitivity and specificity of the assay may not be optimal for clinical purposes, the epidemiological application is promising. The assay had a low false positive rate of 4% (aggregated over HCV genotype) at an AI cut-off of 20% and T = 365 days (see below for further discussion in relation to false positives); similar false positive rates have been described for HIV avidity assays. 39 Given our relatively small sample size (n = 45) for determining the false positive rate, estimation of this parameter could be improved through pooling data from multiple studies. Avidity assays have more use in high-than low-prevalence populations for detection of recent HCV infection. Due to the higher risk of transmission and thus new infections within a high-prevalence population, an assay with low sensitivity can still be a valuable tool. 40 At the population-level, HCV incidence can be estimated from a single cross-sectional prevalence survey using only the assay-based classification of recent infection and the MDRI and false-positive rate parameters. 20 The WHO global hepatitis strategy includes targets for a 90% reduction in incidence between 2015 and 2030 41 ; however, the vast majority of countries lack HCV surveillance systems to monitor progress toward this target. Avidity testing offers a practical and relative low-cost tool to help monitor HCV incidence and assess progress in meeting global targets.
Another potential epidemiological application for the avidity assay described here is during outbreak investigations and in contact tracing.
HCV sequence analysis has demonstrated the relationship between newly infected PWID and their HCV-positive injecting partners. 42 Antiviral therapy offered to selected contacts may help to prevent the further spread of HCV. 43 Avidity assays can inform the extent of recent /ongoing transmission in certain cohorts. For example, an HIV avidity assay has been used during an ongoing HIV outbreak among a homeless PWID population. ; therefore, a switch to different chaotropic agents may reduce the genotype effect. 
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